Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) will present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.
Presentations: May 12, 2026, 10:00–10:30 AM PT (BofA, Las Vegas) and June 8, 2026, 10:40–11:15 AM ET (Goldman Sachs, Miami). Live and replay webcasts will be available on the company investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – CAI
In the Apr 24 session, CAI gained 2.07%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Earnings date notice | Neutral | +0.4% | Announcement of first-quarter 2026 results date and webcast details. |
| Apr 17 | Partnership expansion | Positive | +3.7% | UCSF cancer center joining the Precision Oncology Alliance network. |
| Apr 15 | Clinical access program | Positive | +3.8% | Expansion of Right-In-Time solution to broaden oncology trial access. |
| Apr 08 | AI product launch | Positive | +4.0% | New multimodal AI signature to guide NSCLC chemotherapy decisions. |
| Apr 02 | Diagnostics launch | Positive | +0.8% | Launch of Caris ChromoSeq WGS/WTS assay for myeloid malignancies. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent product, AI and clinical-access updates have been followed by modestly positive next-day moves.
Over the past month, CAI has issued a series of operational and innovation-focused updates. Launches like Caris ChromoSeq on April 2, 2026, a new multimodal AI treatment-guidance signature on April 8, and expansion of the Right-In-Time trial solution on April 15 all saw positive next-day price reactions between 0.84% and 4.05%. Collaborations such as the UCSF POA addition on April 17 and an earnings-date notice on April 20 also drew mild gains, suggesting constructive reception to growth and platform-building news.
Key Terms
precision medicine medical
molecular profiling medical
whole genome sequencing medical
artificial intelligence technical
machine learning technical
high-performance computing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The BofA Securities 2026 Health Care Conference will be held on May 12-14, 2026, in
The Goldman Sachs 47th Annual Global Healthcare Conference will be held on June 8-10, 2026, in
Live and replay webcasts will be available on the Investor Relations section of Caris' website at https://investor.carislifesciences.com.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
Investor Relations:
IR@CarisLS.com
917.689.3511
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-present-at-the-bofa-securities-2026-health-care-conference-and-the-goldman-sachs-47th-annual-global-healthcare-conference-302752499.html
SOURCE Caris Life Sciences